Seattle Genetics (SGEN -3.9%) moves a step closer to FDA approval, but shares stumble after the...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

Seattle Genetics (SGEN -3.9%) moves a step closer to FDA approval, but shares stumble after the FDA files documents (.pdf) asking questions about the extent of the research done on the firm's blood cancer drug.  Medical experts will issue a recommendation to the FDA on Thursday, and a final decision date is set for Aug. 30.